As part of a life-course approach to health, preventive solutions will have an important role to play. Yet, as these approaches may be less tangible than care and treatment, the development of innovations dedicated to prevention can be a bumpy road. How can a product be qualified as preventive and how can its effect be assessed? What are the current frame and regulations concerning these products? What criteria should be taken into consideration in this matter? What business models have proven themselves to be effective? How to identify the players who finance these solutions? Toward which actors are these solutions directed: public health systems, private organisations, private people? To what extent are those products sold directly to consumers?